Exchange: OTC Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-21.71% $0.943
America/New_York / 25 sep 2023 @ 15:59
FUNDAMENTALS | |
---|---|
MarketCap: | 521.35 mill |
EPS: | -0.840 |
P/E: | -1.123 |
Earnings Date: | Nov 12, 2023 |
SharesOutstanding: | 552.66 mill |
Avg Daily Volume: | 0.451 mill |
RATING 2023-10-23 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.123 | sector: PE 29.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -1.123 | industry: PE 31.46 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.567 - 0.845 ( +/- 19.68%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Worthington Alison | Sell | 43 257 | Common Shares |
2023-12-27 | Olson Bryan | Sell | 51 552 | Common Shares |
2023-12-15 | Vita Nicholas | Sell | 1 000 000 | Common Shares |
2023-12-20 | Vita Nicholas | Sell | 100 000 | Common Shares |
2023-12-21 | Vita Nicholas | Sell | 300 000 | Common Shares |
INSIDER POWER |
---|
10.77 |
Last 98 transactions |
Buy: 13 848 242 | Sell: 12 755 331 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.943 (-21.71% ) |
Volume | 2.90 mill |
Avg. Vol. | 0.451 mill |
% of Avg. Vol | 642.87 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Columbia Care Inc. cultivates, manufactures, and provides cannabis products and related services. It offers flowers, edibles, oils, and tablets under the Seed & Strain, Triple Seven, gLeaf, Classix, Press, Amber, and Platinum Label CBD brands. The company holds licenses in 18 jurisdictions in the United States and the European Union. As of June 15, 2022, it operated 131 facilities, including 99 dispensaries and 32 cultivation and manufacturing facilities. The company was founded in 2012 and is headquartered in New York, New York.